Explore the Mechanism of Xiaoyaosan for Treatment of Bipolar Disorder Based on Network Pharmacology, Experimental Validation and Molecular Docking
CNS Neuroscience & Therapeutics · 2026-10 · 32 (10)
DOI: 10.1002/cns.71179 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 28.09.2026. Verfasst von Man Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Jiangmen Traditional Chinese Medicine Hospital of Jinan University, Jiangmen, People's Republic of China. Hauptthemen laut MEDLINE: Molecular Docking Simulation, Drugs, Chinese Herbal, Bipolar Disorder, Network Pharmacology. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Fundamental Research Funds for the Central Universities of Jinan University.
Abstract (Originalsprache)
Aim of the Study Xiaoyaosan (XYS) has significant anti‐inflammatory effects and is widely used for treating depression. However, the multitarget mechanism of XYS in the treatment of bipolar disorder (BD) remains unexplored. In this study, network pharmacology, molecular docking, and experimental validation were integrated to elucidate the mechanisms of XYS and its therapeutic efficacy in BD.
Methods
First, network pharmacology was employed to elucidate the anti‐BD mechanism of XYS. Second, the therapeutic effects of XYS against BD were investigated in a BD mouse model induced by Ank3 gene knockdown combined with chronic social defeat stress (CSDS). Finally, the targets from these predictions were validated in a series of experiments and molecular docking.
Results
First, on the basis of network pharmacology, 120 predicted intersection targets between the targets of XYS and BD‐related targets were identified. The key core targets of the anti‐BD activity of XYS were STAT3, AKT1, IL‐6, and MAPK3. Thus, inflammation pathways might play a critical role in the anti‐BD effects of XYS. Second, XYS clearly inhibited BD activity, which was manifested by a significant alleviation of manic hyperactivity behavior and a significant improvement in depressive hyperactivity behavior in BD model mice. Additionally, the up‐regulation of STAT3, AKT1, IL‐6, and MAPK3 was improved by XYS intervention in a BD mouse model. Moreover, molecular docking results also revealed that XYS showed strong stable binding to key core targets from network pharmacological predictions.
Conclusions
XYS can markedly improve BD through modulation of the expression of the key multitargets STAT3, AKT1, IL‐6, and MAPK3 in inflammation pathways. These novel findings elucidate the anti‐BD mechanism of XYS from the perspective of multiple targets and pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Affiliated Jiangmen Traditional Chinese Medicine Hospital of Jinan University, Jiangmen, People's Republic of China.
- Guangzhou Key Laboratory of Formula-Pattern of Traditional Chinese Medicine, School of Traditional Chinese Medicine, Jinan University, Guangzhou, People's Republic of China.
- Integrated Chinese and Western Medicine Postdoctoral Research Station, Jinan University, Guangzhou, People's Republic of China.
- Henan Province Hospital of Traditional Chinese Medicine, Zhengzhou, People's Republic of China.
- School of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, People's Republic of China.
ORCID-Profile: Man Chen, Jiaxu Chen
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Fundamental Research Funds for the Central Universities of Jinan University
- Huang Zhendong Research Fund for Traditional Chinese Medicine of Jinan University
- China Postdoctoral Science Foundation
Zitieren
APA
Chen, M., Ding, N., Qiu, X., Li, L., Guo, Y., Wang, R., Mo, X., Zou, T., Yu, S., Li, X., & Chen, J. (2026). Explore the Mechanism of Xiaoyaosan for Treatment of Bipolar Disorder Based on Network Pharmacology, Experimental Validation and Molecular Docking. CNS Neuroscience & Therapeutics, 32(10). https://doi.org/10.1002/cns.71179
Vancouver
Chen M, Ding N, Qiu X, Li L, Guo Y, Wang R, et al. Explore the Mechanism of Xiaoyaosan for Treatment of Bipolar Disorder Based on Network Pharmacology, Experimental Validation and Molecular Docking. CNS Neuroscience & Therapeutics. 2026;32(10). doi:10.1002/cns.71179
BibTeX
@article{Chen2026,
author = {Chen, Man and Ding, Nana and Qiu, Xingmin and Li, Lan and Guo, Yali and Wang, Rongyanqi and Mo, Xiaowei and Zou, Tan and Yu, Shangzhen and Li, Xiaojuan and Chen, Jiaxu},
title = {Explore the Mechanism of Xiaoyaosan for Treatment of Bipolar Disorder Based on Network Pharmacology, Experimental Validation and Molecular Docking},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
volume = {32},
number = {10},
doi = {10.1002/cns.71179}
}
EUVIMED